AI-generated summary
The authors developed a compact light device delivering 660 and 830 nm irradiation to activate platelet-rich plasma ex vivo, testing several fluences and incubation times. They report reproducible biochemical changes, with Raman spectral signatures at 72 hours correlating with ELISA-measured growth factor release. The study is a proof-of-concept framework, and the abstract does not report participant numbers or clinical outcomes.
- Who or what was studied
- Platelet-rich plasma samples treated ex vivo (no human or animal participant count stated)
- Wavelengths
- 660, 830 nm
- Limits stated in the abstract
- The abstract describes an ex vivo proof-of-concept study with no stated sample size or clinical outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 830 nm
- Energy density (fluence)
- 15 J/cm2
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Fluence, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.